Key Dates

Related Announcements

PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute on Aging (NIA)

National Cancer Institute (NCI)

National Eye Institute (NEI)

National Heart, Lung, and Blood Institute (NHLBI)

National Human Genome Research Institute (NHGRI)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute on Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of General Medical Sciences (NIGMS)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Library of Medicine (NLM)

Fogarty International Center (FIC)

National Center for Complementary and Integrative Health (NCCIH)

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)

Purpose

The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimer’s disease and its related dementias (AD/ADRD) frontotemporal dementia, Lewy body dementia, vascular cognitive impairment with dementia, and multiple etiology dementias to allow the research to develop such a focus. Active awards with project end dates in FY 2022 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2021. Please note that a few ICs limit no-cost extensions in the final non-competing year of an award. For that reason, it is important to contact staff at the Institute supporting the award when planning the request.

As administrative supplements, the work proposed needs to be within the scope of the research or training that is already supported. Center awards and resource awards are most likely to be able to justify these supplements, as they tend to have a broad content scope. Some research grants will also qualify if the current research is on a related topic (such as cognitive decline in aging, caregiving, the biology of neurodegeneration, genetics, imaging, computational methods, pain perception, or biostatistical tools that have application to research on AD/ADRD). NIA hosts a website that provides details on how Alzheimer’s disease and its related dementias are defined and some examples of currently supported research. Awardees are expected to seek competing support to continue promising leads from the research supported through the supplement.

Awards that currently focus on research on Alzheimer’s disease or its related dementias are not eligible for this program. If an investigator is uncertain whether the project does carry an Alzheimer’s focus as defined by NIH, then the investigator may contact the appropriate program officer who can check that status. (For example, the parent award may be focusing on cognitive change due to chemotherapy in cancer patients. Does that research have a current focus on Alzheimer’s or its related dementias? Contact the program officer for the award to check its status.)

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-18-591 must be followed, with the following additions:

• Application Due Date October 16, 2020, by 5:00 PM local time of applicant organization.
• For funding consideration, applicants must include NOT-AG-20-034 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Only electronic submissions will be accepted for this funding opportunity. Use one of the methods described in PA-18-591. Paper submissions and applications submitted as attachments will be returned.
• Requests may be for one year of support only.
• Individual requests can be no more than $250,000 in direct costs exclusive of Facilities and Administrative costs on sub-contracts. Though supplement requests are not limited to one per award, we will consider substantial additional funding to an award as beyond the scope of the funded award.
• Applicants may apply for more than one supplement to a given parent grant/award, provided they are scientifically distinct.
• .
• The Research Strategy section of the application is limited to 6 pages.

• As part of the application, investigators must submit an abstract of the proposed research that shows the relevance to Alzheimer’s disease and/or its related dementias. Place the abstract in the Project Summary/Abstract section of the SF424 (R&R) form. The work may include pilot projects or resource development.

Institute-, Center-, and Office-specific Instructions

National Human Genome Research Institute:

NHGRI will support studies that provide generalizable methods and knowledge in all three scientific areas of genome sciences, genomic medicine, and genomics and society. Work proposed in supplements must fall within the scope of the aims of the NHGRI grant to be supplemented

Investigators are encouraged to contact their NHGRI Scientific Program Officer for the grant to be supplemented before preparing an application to discuss the relevance of the proposed research to the parent grant and to the Institute's research priorities.

National Cancer Institute:

Aging is a significant risk factor for most adult-onset cancers and Alzheimer’s disease and its related dementias. Examples of research areas in NCI’s award portfolio that might qualify for this administrative supplement program include, but are not limited to, the following:

• Biologic and genetic mechanisms of cancer and aging
• Preclinical drug/drug combination development in an aging context
• Cancer- and cancer treatment-related neurocognitive function
• Treatment tolerability, toxicity, and symptom management
• Behavioral and social risk factors and outcomes
• Attention, sensation, and perception
• Geriatric assessment
• Epidemiologic cohort studies of cancer risk or survivorship
• Premature/accelerated/accentuated aging in those with a history of cancer
• Financial toxicity
• Cancer caregiving
• Clinical trial development for, and accrual of, older adults
• Transitions in care and models of health care delivery
• Multimorbidity/multiple chronic conditions
• Computational methods, biostatistical tools, and measurement development
• Imaging and image-guided cancer intervention

While not a research area per se, the inclusion of underserved and understudied populations in research studies is encouraged.

National Institute of Child Health and Human Development:

NICHD is particularly interested in studies that explore the linkages between early life events and later development of Alzheimer’s disease and its related dementias (AD/ADRD). Topics of interest include, but are not limited to, the following:

• The linkages between pregnancy complications such as hypertension and preeclampsia and later development of dementia
• The connection between pediatric CNS infections and post-infectious complications and/or effects of in utero exposure to infection/inflammation and later development of dementia
• The role of head trauma and brain injury in the later development of dementia and the possible benefit of rehabilitation interventions for cognition and gait/balance in AD/ADRD
• The significantly increased risk of Alzheimer’s disease in adults with Down syndrome
• Population-representative data that examines how cognitive changes in later life are affected by exposures and experiences during early life, and by social determinants directly and through interaction with biological variables
• The use of statistical modeling to address issues related to the development and treatment of cognitive decline leading to AD/ADRD

Investigators are encouraged to contact their NICHD Scientific Program Officer before preparing an application to discuss the relevance of the proposed research to the parent grant and to the Institute's research priorities

Review Process

Each IC will conduct administrative reviews of applications from their IC separately. NIA will make funds available to each of the participating ICs, provided that sufficient funds are available.

Criteria:

1. Is the work proposed within the scope of the active award?
2. Is the work proposed focused on Alzheimer’s disease or its related dementias?
3. Is the work likely to stimulate additional activity leading to progress on any, or all, of these dementias?

Inquiries

Please direct all inquiries to:

Rene Etcheberrigaray
National Institute on Aging (NIA)
Telephone: 301-451-9798
Email: [email protected]

Paige Green
National Cancer Institute (NCI)
Telephone: 240-276-6899
Email: [email protected]

Martha Flanders
National Eye Institute (NEI)
Telephone: 301-451-2020
E-mail: [email protected]

Jue Chen
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0550
Email: [email protected]

Bettie Graham
National Human Genome Research Institute (NHGRI)
Telephone: 301-496-7531
E-mail: [email protected]

Abraham Bautista
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-9737
E-mail: [email protected]

Michael Minnicozzi
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3532
Email: [email protected]

Marisol Espinoza-Pintucci
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-827-6959
Email: [email protected]

Randy King
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone:301-451-4780
E-mail: [email protected]

Melissa Parisi
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-496-1383
Email: [email protected]

Judith Cooper
National Institute on Deafness and Other Communication Disorders (NIDCD)
Telephone: 301-496-5061
E-mail: [email protected]

Preethi Chander
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone: 301-827-4620
E-mail: [email protected]

Roger Little
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1315
Email: [email protected]

Brad Cooke
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-480-9896
Email: [email protected]

Jonathan Hollander
National Institute of Environmental Health Sciences (NIEHS)
Telephone: 984-287-3269
E-mail: [email protected]

Paula Flicker
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-594-0574
Email: [email protected]

Jovier Evans
National Institute of Mental Health (NIMH)
Telephone: 301-443-1369
E-mail: [email protected]

Roderick Corriveau
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
E-mail: [email protected]

Lois Tully
National Institute of Nursing Research (NINR)
Telephone: 301-594-5968
E-mail: [email protected]

Priscah Mujuru
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-9765
Email: [email protected]

Hua-Chuan Sim
National Library of Medicine (NLM)
Telephone: 301-594-4882
E-mail: [email protected]

Marya Levintova
Fogarty International Center (FIC)
Telephone: 301-496-1653
E-mail: [email protected]

Yisong Wang, Ph.D.
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-480-9483
E-mail: [email protected]

Oleg Mirochnitchenko
Office of Research Infrastructure Programs (ORIP)
Telephone: 301-435-0748
Email: [email protected]